Swapnil Dylan Fernandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Swapnil Dylan Fernandes has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anoop Narayanan Vadakkepushpakath
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Department of Pharmaceutics, Mangalore, Karnataka-575018, India
3 shared publications - Lovely Joylen Castelino
Department of Pharmaceutical Regulatory Affairs, Nitte Gulabi Shetty Memorial Institute of Pharmaceutical Sciences, NITTE (Deemed to be University), Mangaluru, India
3 shared publications - Ravi Gundadka Shriram
Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore 575018, Karnataka, India
2 shared publications Akhilesh Dubey
Department of Pharmaceutical Regulatory Affairs, N.G.S.M. Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India
1 shared publicationD S. Sandeep
1 shared publicationNarayana R. Charyulu
Department of Pharmaceutical Regulatory Affairs, N.G.S.M. Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Deralakatte, Mangaluru, Karnataka, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2020
- Published by Korean Vaccine Society in Clinical and Experimental Vaccine Research
- Vol. 9 (2) , 69-75
Vaccines in the United States: a systematic review on history of evolution, regulations, licensing, and future challenges
Sathyanarayana SD, et al. Clin Exp Vaccine Res. 2020 Jul;9(2):69-75. https://doi.org/10.7774/cevr.2020.9.2.69
- 1 January 2020
- Published by Korean Vaccine Society in Clinical and Experimental Vaccine Research
- Vol. 9 (2) , 69-75
Open AccessVaccines in the United States: a systematic review on history of evolution, regulations, licensing, and future challenges
Sathyanarayana SD, et al. Clin Exp Vaccine Res. 2020 Jul;9(2):69-75. https://doi.org/10.7774/cevr.2020.9.2.69
- 1 April 2019
- Published by Elsevier in Trends in Food Science & Technology
- Vol. 86, 579-585
The emergence of India as a blossoming market for nutraceutical supplements: An overview
- 1 April 2019
- Published by Elsevier in Trends in Food Science & Technology
- Vol. 86, 579-585
The emergence of India as a blossoming market for nutraceutical supplements: An overview
- Open Access
- 1 January 2019
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 10
Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada
Regulatory approvals for the marketing of medicinal products authorize medical practitioners to prescribe drugs to a group of patients that are defined within the license of the medicinal product. However, such prescriptions are carried out in a controlled manner. Prior to being approved, the medicinal product will have been evaluated in a population pool containing fewer than 5,000 patients and in a predesigned environment where several factors may be lacking, such as the absence of women of childbearing potential, geriatric patients and paediatric patients. Therefore, it is not surprising that several major adverse drug reactions are detected only when the product has been prescribed to the general population. National and international regulatory bodies have devised systems for monitoring medicinal products after marketing, commonly known as postmarketing surveillance systems. Postmarketing surveillance refers to the process of monitoring the safety of drugs once they reach the market, after the successful completion of clinical trials. The primary purpose for conducting postmarketing surveillance is to identify previously unrecognized adverse effects as well as positive effects. The Yellow Card scheme, practiced in the United Kingdom and the Canada Vigilance Program adopted in the Canadian jurisdiction, are two of the most successful postmarketing surveillance systems implemented across the world. Therefore, this article intends to discuss postmarketing surveillance and its role in the context of the United Kingdom and Canadian jurisdictions with a view on presenting key aspects and measures that are employed for operating an efficient postmarketing surveillance system in regulated markets.
- 1 January 2019
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 10
Open AccessPostmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada
Regulatory approvals for the marketing of medicinal products authorize medical practitioners to prescribe drugs to a group of patients that are defined within the license of the medicinal product. However, such prescriptions are carried out in a controlled manner. Prior to being approved, the medicinal product will have been evaluated in a population pool containing fewer than 5,000 patients and in a predesigned environment where several factors may be lacking, such as the absence of women of childbearing potential, geriatric patients and paediatric patients. Therefore, it is not surprising that several major adverse drug reactions are detected only when the product has been prescribed to the general population. National and international regulatory bodies have devised systems for monitoring medicinal products after marketing, commonly known as postmarketing surveillance systems. Postmarketing surveillance refers to the process of monitoring the safety of drugs once they reach the market, after the successful completion of clinical trials. The primary purpose for conducting postmarketing surveillance is to identify previously unrecognized adverse effects as well as positive effects. The Yellow Card scheme, practiced in the United Kingdom and the Canada Vigilance Program adopted in the Canadian jurisdiction, are two of the most successful postmarketing surveillance systems implemented across the world. Therefore, this article intends to discuss postmarketing surveillance and its role in the context of the United Kingdom and Canadian jurisdictions with a view on presenting key aspects and measures that are employed for operating an efficient postmarketing surveillance system in regulated markets.
- 1 January 2019
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 15 (1) , 109-113
A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials
- 1 January 2019
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 15 (1) , 109-113
A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials
- 1 January 2018
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 11 (7) , 3209
Good Clinical Practices: An Indian Perspective
- 1 January 2018
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 11 (7) , 3209
Good Clinical Practices: An Indian Perspective